ICON plc (NASDAQ: ICLR) sets Q1 2026 earnings release and conference call dates
Rhea-AI Filing Summary
ICON plc, a global clinical research organization based in Dublin, plans to release its first quarter 2026 financial results after the market closes on Tuesday, June 23, 2026. The company will host a conference call and webcast to discuss results on Wednesday, June 24, 2026 at 8:00am ET, with access and any updates available in the Investor section of its website.
ICON describes itself as a world-leading clinical research organization providing integrated consulting, clinical development, commercialization and post-marketing solutions to life sciences, government and public health clients worldwide. As of December 31, 2025, it employed approximately 40,100 employees across 97 locations in 55 countries.
Positive
- None.
Negative
- None.
Key Figures
Q1 2026 results release date: June 23, 2026
Earnings call time: 8:00am ET
Earnings call date: June 24, 2026
+4 more
7 metrics
Q1 2026 results release date
June 23, 2026
Financial results released after market close
Earnings call time
8:00am ET
First quarter 2026 conference call on June 24, 2026
Earnings call date
June 24, 2026
Conference call and webcast to discuss Q1 2026 results
Employees
40,100 employees
As of December 31, 2025
Global locations
97 locations
Company footprint as of December 31, 2025
Countries of operation
55 countries
Operational presence as of December 31, 2025
Headquarters
Dublin, Ireland
Corporate headquarters location
Key Terms
clinical research organization, forward-looking statements, safe harbor provisions, contracted revenue, +1 more
5 terms
clinical research organization financial
"ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization, today announced"
A clinical research organization (CRO) is a company that manages and runs human studies for medicines, medical devices and diagnostics on behalf of developers and sponsors. Think of a CRO as an outsourced project manager and contractor for testing — they recruit patients, collect data, handle regulatory paperwork and keep studies on schedule. Investors watch CROs because their quality and capacity affect development speed, cost and regulatory risk, which in turn influence when and whether products reach the market.
forward-looking statements regulatory
"Statements included herein which are not historical facts are forward-looking statements."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
safe harbor provisions regulatory
"Such forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995."
Safe harbor provisions are rules or legal protections that shield companies or individuals from certain penalties or liabilities when they follow specific guidelines or procedures. They provide a sense of security, encouraging compliance and innovation by reducing the fear of legal repercussions if they act in good faith. For investors, these provisions help ensure that companies are transparent and accountable without the risk of unfair punishment for honest mistakes.
contracted revenue financial
"Examples of forward-looking statements include, but are not limited to, statements regarding the following: contracted revenue;"
Contracted revenue is the amount of money a business expects to receive because customers have signed binding agreements for goods or services over a set period. For investors it shows how much future cash is already promised, reducing uncertainty about sales — like having customers hand you a schedule of payments in advance — which helps assess growth potential, valuation and risk compared with one-off or uncertain sales.
regulatory environment regulatory
"changes in the regulatory environment, exchange rate fluctuations, inflation and rising labor costs."
The collection of laws, rules, agencies and approval processes that govern how a business operates, sells products, or raises money. It matters to investors because changes in those rules can raise costs, block or speed product approvals, limit market access or create legal risk—like new traffic laws that can make a route slower, more expensive or outright impassable for a company’s plans.
FAQ
When will ICON plc (ICLR) report its first quarter 2026 financial results?
ICON plc will release its first quarter 2026 financial results after the market closes on Tuesday, June 23, 2026. The company will then discuss these results on a conference call and webcast the following morning, allowing investors to hear management’s commentary and outlook.
When is ICON plc (ICLR) holding its Q1 2026 earnings conference call?
ICON plc will hold its first quarter 2026 earnings conference call and webcast on Wednesday, June 24, 2026 at 8:00am ET. The company will discuss its financial results and performance, with live access links provided in the Investor section of its corporate website under “Events”.
How can investors access ICON plc’s Q1 2026 earnings webcast?
Investors can access ICON plc’s Q1 2026 earnings webcast via links posted in the Investor section of the company’s website under “Events”. A replay of the conference call will be available approximately one hour after the call concludes, offering flexibility for different time zones.
What business does ICON plc (ICLR) operate in?
ICON plc is a world-leading clinical research organization providing consulting, clinical development, commercialization and post-marketing solutions. It serves pharmaceutical, biotechnology, medical device, government and public health organizations worldwide, helping move therapies from molecule to medicine and aiming to improve patient outcomes across many therapeutic areas.
How large is ICON plc’s global workforce and footprint?
As of December 31, 2025, ICON plc employed approximately 40,100 employees across 97 locations in 55 countries. This broad global footprint supports its clinical research operations and service delivery for pharmaceutical, biotechnology, medical device, government and public health clients around the world.
Who is the investor relations contact for ICON plc (ICLR)?
ICON plc lists Kate Haven, Vice President Investor Relations, as its primary investor contact, with a telephone number of +1888 381 7923. Investors and analysts can use this contact for questions about financial results, corporate strategy, or upcoming events such as the Q1 2026 earnings call.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Commission File Number: 333-08704
ICON plc
(Translation of registrant's name into English)
South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Ireland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Exhibit List
Exhibit Description
99.1 ICON Schedules First Quarter 2026 Earnings Conference Call
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ICON plc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Date: June 17, 2026 | By: | /s/ Nigel Clerkin | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Name: | Nigel Clerkin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Title: | Chief Financial Officer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exhibit 99.1
ICON Schedules First Quarter 2026 Earnings Conference Call
Dublin, Ireland, June 17, 2026 – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization, today announced that it will release its financial results for the first quarter 2026 after the market closes on Tuesday, June 23, 2026. The company will hold a conference call and webcast to discuss its financial results and performance on Wednesday, June 24, 2026 at 8:00am ET.
Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “Events”. A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.
About ICON plc
ICON plc is a world-leading clinical research organization. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,100 employees in 97 locations in 55 countries as of December 31, 2025. For further information about ICON, visit: www.iconplc.com.
Statements included herein which are not historical facts are forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, but are not limited to, statements regarding the following: contracted revenue; the repayment of indebtedness; the company's expectations regarding business momentum, market opportunity, demand trends, growth, and commercial performance; and the company's expectations with respect to its long-term value creation and competitive positioning. You can identify many forward-looking statements by words such as “aims,” “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “focused,” “guidance,” “intends,” “look,” “may,” “opportunities,” “plans,” “positions,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “would” and other similar expressions and the negatives of such expressions. However, not all forward-looking statements contain these words. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. The forward looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, our results could be materially adversely affected. The risks and uncertainties include, but are not limited to, dependence on the pharmaceutical industry and certain clients, the need to regularly win projects and then to execute them efficiently and correctly, the challenges presented by rapid growth, competition and the continuing consolidation of the industry, the impact of market conditions on demand for the company's services, risks related to the company's ability to execute on its commercial strategy and maintain relationships with large pharmaceutical customers, and risks relating to the company's strategic partnerships, the dependence on certain key executives, changes in the regulatory environment, exchange rate fluctuations, inflation and rising labor costs. Please also refer to the section entitled "Risk Factors" of our Annual Report on Form 20-F for the year ended December 31, 2025 for a discussion of some of the principal risks that could adversely affect our business, operations and financial results. The company’s forward-looking statements speak only as of the date of this document or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.
Source: ICON plc
Contact: Kate Haven Vice President Investor Relations +1888 381 7923
ICON/ICLR-G